Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
anticonvulsant |
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States gptkb:FDA |
| gptkbp:ATCCode |
gptkb:N03AX39
|
| gptkbp:brand |
gptkb:Xcopri
|
| gptkbp:CASNumber |
1138245-13-2
|
| gptkbp:developer |
gptkb:SK_Biopharmaceuticals
|
| gptkbp:eliminationHalfLife |
50-60 hours
|
| gptkbp:hasMolecularFormula |
C10H10ClN3O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cenobamate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
modulation of voltage-gated sodium channels
positive allosteric modulation of GABAA receptors |
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:proteinBinding |
60%
|
| gptkbp:PubChem_CID |
gptkb:DB15101
71287773 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue headache drowsiness double vision |
| gptkbp:UNII |
4B6X41759U
|
| gptkbp:usedFor |
treatment of partial-onset seizures
|
| gptkbp:bfsParent |
gptkb:SK_Biopharmaceuticals
|
| gptkbp:bfsLayer |
6
|